ABBV — AbbVie Inc. catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

11 verified catalyst event(s) for AbbVie Inc. (ticker ABBV). Each is linked to its official source. Verified as of 2026-08-06.

Next verified catalyst

2026-09-01 — A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Throu · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-09 (month) in 26d ESTIMATED	READOUT A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug M Phase 3 · Juvenile Psoriatic Arthritis	ABBV AbbVie Inc.	Adalimumab, Risankizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-10 (month) in 2mo ESTIMATED	READOUT Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD Phase 3 · AMD, nAMD	ABBV AbbVie Inc.	ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11 (month) in 3mo ESTIMATED	READOUT Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax Phase 2 · Chronic Lymphocytic Leukemia (CLL)	ABBV AbbVie Inc.	Venetoclax, Obinutuzumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11 (month) in 3mo ESTIMATED	READOUT Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Fo Phase 2 · High Grade Ovarian Cancer, Primary Peritoneal Cancer	ABBV AbbVie Inc.	Mirvetuximab soravtansine, Carboplatin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11 (month) in 3mo ESTIMATED	READOUT Study to Evaluate Adverse Events, and Change in Disease Activity, When Intraveno Phase 2 · Hepatocellular Carcinoma	ABBV AbbVie Inc.	Budigalimab, Livmoniplimab, Lenvatinib,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11 (month) in 3mo ESTIMATED	READOUT Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 Phase 2 · Generalized Anxiety Disorder (GAD)	ABBV AbbVie Inc.	ABBV-932, Antidepressant Therapy (ADT)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12 (month) in 4mo ESTIMATED	READOUT Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bow Phase 2 · Irritable Bowel Syndrome	ABBV AbbVie Inc.	Eluxadoline	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12 (month) in 4mo ESTIMATED	READOUT Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administere Phase 2/3 · AMD, nAMD	ABBV AbbVie Inc.	ABBV-RGX-314, ABBV-RGX-314, Ranibizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12 (month) in 4mo ESTIMATED	READOUT Study to Assess Adverse Events and Change in Disease Activity in Previously Trea Phase 2 · Unresectable Metastatic Colorectal Cancer	ABBV AbbVie Inc.	ABBV-400, Bevacizumab, Folinic Acid, Flu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12 (month) in 4mo ESTIMATED	READOUT A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adoles Phase 3 · Hidradenitis Suppurativa	ABBV AbbVie Inc.	Lutikizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12-18 in 4mo ESTIMATED	READOUT A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo i Phase 2 · Migraine	ABBV AbbVie Inc.	MEDI0618	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change